Statement re social media reports

RNS Number : 3894L

ValiRx PLC

29 April 2020

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Statement re social media reports

London, UK ., 29 April 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, notes the recent movement in the Company's share price and speculative comments posted on social media in respect of a potential Joint Venture in relation to the Company's non-core intellectual property - GeneICE, TRAC and BioFit.

The Company confirms that it is in talks with a third-party in relation to a Joint Venture.  However, there is no certainty the talks will conclude in a successful manner, nor that in the event that the Joint Venture is agreed, that the terms will be favourable to the Company.

-ENDS-

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Kevin Alexander - Non-executive Director
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: [phone]
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: [phone]

 

END

 

 

MSCSEUFMUESSEDL